Absci Corporation Announces Q4 and Full Year 2024 Results Release Date and Participation in Healthcare Forum

Absci Corporation Announces Financial Results Release Date

Absci Corporation (NASDAQ: ABSI), a pioneering company in the field of AI-driven drug creation, has set the date for the release of its fourth quarter and full year 2024 financial and operating results. The company will disclose these updates after the market closes on Tuesday, March 18, 2025 1

1

Following the release, Absci's management team will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the company's business developments, financial performance, and future outlook. Interested parties can access the live audio webcast on the company's investor relations website at investors.absci.com 2

2

Participation in KeyBanc Capital Markets Healthcare Forum

In addition to the financial results announcement, Absci has confirmed its participation in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. The company's management is scheduled to engage in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) 3

3

This participation provides an opportunity for Absci to showcase its innovative approach to drug development and discuss its position in the rapidly evolving field of AI-driven pharmaceuticals. Investors and interested parties can access a live and archived webcast of the fireside chat through Absci's investor relations website.

Absci's Innovative Approach to Drug Creation

Absci Corporation describes itself as a "data-first generative AI drug creation company" that combines artificial intelligence with scalable wet lab technologies. The company's unique selling proposition lies in its ability to create better biologics for patients at an accelerated pace 1

1

At the core of Absci's operations is its Integrated Drug Creation™ platform, which aims to revolutionize the drug development process. This platform is designed to:

1. Accelerate time to clinic
2. Increase the probability of success
3. Simultaneously optimize multiple drug characteristics

The company's approach allows for the screening of billions of cells per week, enabling a rapid transition from AI-designed candidates to wet lab-validated candidates in as little as six weeks 2

2

Related Stories

Absci Accelerates AI-Driven Drug Discovery through Oracle and AMD Collaboration

AMD Invests $20 Million in Absci to Accelerate AI-Driven Drug Discovery

OmniAb to Showcase AI-Powered Antibody Discovery Platform at Upcoming Investor Conferences

ImmunoPrecise Antibodies Reschedules Q3 Fiscal 2025 Financial Results Amid AI-Powered Antibody Discovery Progress

Company Structure and Global Presence

Absci's operations span across multiple locations, reflecting its commitment to leveraging diverse talent and resources:

1. Headquarters: Vancouver, Washington
2. AI Research Lab: New York City
3. Innovation Center: Zug, Switzerland

This strategic positioning allows Absci to tap into various pools of expertise and maintain a global perspective on drug development and AI innovation 3

3